Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “THROMBOEMBOLISM”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,135 records · Page 63Linked to original sources

Venous thromboembolism after penetrating chest trauma is not a cause of early death.

BACKGROUND: Venous thromboembolism has been recognized as a potentially life-threatening complication following major thoracic trauma. Little or no attention has been directed at the difference in rates of venous thromboembolism in subjects with penetrating and nonpenetrating chest trauma. METHODS: The reported experience with venous thromboembolism in subjects with chest trauma has not segregated the effect penetrating vs. closed chest trauma. The influence of long-term hospitalization to the formation deep vein thrombosis, pulmonary embolism or subsequent death. The present study evaluated the causes of early death occurring within 96 hours of hospitalization for penetrating chest trauma. The clinical records and autopsy reports of 32 individuals, who died within 96 hours of admission to hospital for penetrating chest trauma, were evaluated for the presence of deep vein thrombosis and pulmonary embolism. RESULTS: All 32 subjects were male with an average age of 31 years. Eighty percent were successfully resuscitated in the emergency room. Forty percent (40%) required an emergency or operating room thoracotomy. The initial revised trauma score (RTS) was below 4 in each case. Thirty-two percent (32%) of the patients died on the fourth day; 48% died between 1 and 3 days of admission and 20% died in the emergency room. None of the patients had any clinical signs or evidence of deep vein thrombosis or pulmonary embolism. Moreover, the autopsy findings were negative for deep vein thrombosis and pulmonary embolism. CONCLUSION: Deep vein thrombosis and pulmonary embolism is rarely a cause of death within the initial 96 hours of hospitalization in individuals sustaining penetrating chest trauma.

Adolescent↗

Thromboembolic prophylaxis in moderate-risk patients undergoing elective abdominal surgery: decision and cost-effectiveness analyses.

We conducted a retrospective, literature-based decision analysis to compare the cost-effectiveness of conventional low-dose heparin, dalteparin, and intermittent pneumatic compression (IPC) as thromboembolic prophylaxis to a no-prophylaxis option in patients at moderate risk of developing thromboembolic complications after major elective abdominal surgery. The analysis was conducted through an institutional perspective. Probability and incidence rate data were summarized from the literature. Cost data were obtained from the Detroit Medical Center's cost accounting systems and from national diagnosis-related group estimates. Mortality and complications avoided were the main outcome measures on which cost-effectiveness was based. Overall costs associated with conventional low-dose heparin, dalteparin, intermittent pneumatic compression, and no prophylaxis were $84, $122, $102, and $112, respectively in the primary analysis, which included costs of labor. Corresponding cost-effectiveness ratios in terms of costs/complication-free patient were $86, $124, $103, and $118, respectively. Compared with no prophylaxis, incremental cost-effectiveness analysis in terms of cost/mortality avoided involved savings of $6087 and $3125 with conventional low-dose heparin and IPC, respectively, and expenses of $2857 with dalteparin. A secondary analysis excluding costs of labor showed similar results. The results of the study consistently showed conventional low-dose heparin to provide the most cost-effective thromboembolic prophylaxis of the methods considered in terms of reducing both morbidity and mortality in the patient population studied.

Cost-Benefit Analysis↗

[Oral contraception and menopausal hormone replacement: effects on hemostasis and risk of venous thromboembolism].

The estrogen component of oral contraceptives enhances both coagulation and fibrinolysis. These contradictory effects result in activation of coagulation and an increased risk of venous thromboembolism. The relative risk is about 4-fold as compared with a nonuser of the same age. However, the risk of deep vein thrombosis or pulmonary embolism attributable to the pill is small (2 cases per 10,000 users per year). Pills containing a progestagen of the so-called 3rd generation seem to increase the risk by an additional factor of 2. Though small, the risk of venous thromboembolism makes it necessary before any oral contraceptive prescription to take a thorough personal and family history (including risk factors) and to study the risk-benefit ratio on an individual basis. Moreover, patients should receive detailed information on the evaluation. Postmenopausal hormone replacement therapy does not induce significant hemostatic changes (especially with transdermal application) and is not associated with a proven risk of venous thromboembolism. Venous risk factors thus do not contraindicate the use of hormone replacement therapy, except perhaps in the immediate (one-year?) period after an acute event.

Adult↗

[Prevention of thromboembolism in patients with atrial fibrillation].

Atrial fibrillation is a disorder of the cardiac rhythm associated with an increased risk of thromboembolism. Several studies in the past confirmed that anticoagulation or also antiaggregation therapy is associated in these patients with a reduced incidence of cerebrovascular attacks and peripheral embolism. For a more objective assessment of the risk of individual patients risk factors of thromboembolism in atrial fibrillation were defined. They include cardiac insufficiency, hypertension, a history of embolism, left atrial dilatation, systolic dysfunction of left ventricular hypertrophy and spontaneous echo contrast. This risk stratification of patients with atrial fibrillation is the basis for correct selection of subsequent treatment. In patients without risk factors treatment with acetylsalicylic acid can be recommended, if older than 60 years. In younger patients no treatment is necessary for prevention of thromboembolism in this group. In the presence of one or several risk factors permanent anticoagulation treatment with a target value of INR 2.5 is necessary. In patients with atrial fibrillation associated with a congenital or acquired heart disease warfarin is administered with a target value of INR 3-4. The same approach is used in patients with chronic and paroxysmal atrial fibrillation.

Atrial Fibrillation↗

Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Ardeparin Arthroplasty Study Group.

UNLABELLED: We performed a double-blind, randomized clinical trial to compare the efficacy and safety of three different subcutaneous (s.c.) low molecular weight heparin doses (ardeparin sodium 25, 35, or 50 anti-Xa U/kg twice daily [BID]) to adjusted-dose warfarin (international normalized ratio [INR] = 2.0 to 3.0), as venous thromboembolism prophylaxis after total knee replacement surgery. The primary endpoint was total venous thromboembolism prevalence, defined as deep vein thrombosis discovered at postoperative venography of the operated leg, or symptomatic, objectively-documented pulmonary embolism. Of 860 patients randomized, 680 (79%) had an evaluable venogram or pulmonary embolism. The total venous thromboembolism prevalence was significantly greater among patients prophylaxed with warfarin compared to ardeparin 50 BID (38% vs 27%, p = 0.019); the prevalence among ardeparin 25 BID (37%) and 35 BID (28%) patients was similar to warfarin and ardeparin 50 BID patients, respectively. Overt bleeding occurred in 22 (7.9%) ardeparin 50 BID patients compared to 12 (4.4%) warfarin patients (p = 0.08), and in seven ardeparin 25 and 35 BID patients each (5.2% and 5.0%, respectively). Compared to the warfarin group, blood loss was significantly greater in the ardeparin 50 and 25 BID groups, and not different in the ardeparin 35 BID group. CONCLUSIONS: Postoperative, unmonitored, fixed-dose ardeparin 50 anti-Xa U/kg s.c. BID is significantly more effective than adjusted-dose warfarin for this indication. Although overt bleeding among warfarin and ardeparin 50 BID patients did not differ significantly, ardeparin 50 BID patients had significantly greater blood loss. Ardeparin 35 anti-Xa U/kg s.c.BID may provide efficacy similar to ardeparin 50 anti-Xa U/kg s.c. BID but with reduced bleeding.

Adult↗

The risk of venous thromboembolism in the orthopedic patient: epidemiological and physiological data.

Venous thromboembolism is responsible for 500,000 deaths annually in industrialized countries. It is probably the most common preventable cause of death in elective orthopedic surgery patients. Rates of deep vein thrombosis (DVT) and fatal pulmonary embolism (PE) in unprotected orthopedic patient populations are high. The overall DVT rate is > 40% in patients undergoing hip or knee arthroplasty or suffering from multiple injuries. The proximal DVT rate for these patients is > or = 15%, and the fatal PE rate is > or = 1%. Risk factors associated with venous thromboembolism are related to the vascular injury, activation of blood coagulation, and venous stasis. Lower extremity orthopedic procedures carry a risk greater than that of surgery itself. Thus, orthopedic patients are at high risk for venous thromboembolic conditions. A systematic assessment of this risk should be performed in every patient, and an appropriate management plan should be implemented.

Humans↗

Resistance to activated protein C as pathogenic factor of venous thromboembolism.

Venous thromboembolism is a serious health problem and a significant cause of morbidity and mortality. It is associated with certain situations such as surgery, trauma, immobilization, obesity, the use of oral contraceptives, pregnancy and puerperium. In addition, genetic factors have been found to be important in the pathogenesis of venous thrombosis and pulmonary embolism. Until recently, the main genetic defects known to be associated with thromboembolism were antithrombin III, protein C and protein S deficiency accounting together for about 10% of the cases. In 1993 Dahlbäck et al. reported a familial thrombophilia due to a previously unrecognized mechanism characterized by an increased resistance to anticoagulant action of activated protein C (APC). APC-resistance is highly prevalent in general population (2-7%) and in its heterozygous form leads to a life-long hypercoagulable state and 5-10 fold increased risk of thrombosis. It is a major basis for venous thromboembolism and is found in 17 to 64% of patients with inherited thrombophilia.

Animals↗

[Heparins and curative treatment of venous thromboembolic disease: meta-analysis].

Heparin treatment of venous thromboembolic disease has been validated since 1960. Nevertheless no study was sufficient to determine an optimal therapeutic schedule between sub-cutaneous (SC) unfractionated heparin (UFH), intravenous (IV) UFH and low molecular weight heparin (LMWH). One meta-analysis showed a significant risk reduction of recurrent thromboembolic events (OR = 0.58, CI 95 per cent [0.34-0.99]) and a non-significant risk reduction of haemorrhagic events (OR = 0.78 [0.40-1.52]) with UFH SC compared to UFH IV, but homogeneity testing was significant (p < 0.001). Some discrepancy was shown between the results of the three metaanalyses which compared LMWH to UFH according to the selection criteria of clinical trials used. With an exhaustive selection, LMWH involved a non-significant risk reduction of recurrent thromboembolic events (OR = 0.66 [0.41-1.07], p = 0.09), and a non-significant risk reduction of haemorrhagic events (OR = 0.65 [0.36-1.16], p = 0.15). So no definitive conclusion could be drawn but it seems that UFH can be recommended whatever the administration route or LMWH for deep vein thrombosis treatment.

Anticoagulants↗

Prothrombin fragment F1+2 is not predictive for recurrent venous thromboembolism.

It would be important to estimate in advance the risk of recurrent thrombosis. Deficiencies of antithrombin, protein C or protein S, or resistance to activated protein C are associated with a biochemically detectable prethrombotic state. It is thus far unknown whether in patients with a history of thromboembolism but without a defined clotting abnormality a heightened coagulation activation is detectable. We investigated the value of prothrombin fragment F1+2 (F1+2) as a predictor of recurrent venous thromboembolism. Furthermore, we compared the F1+2 levels of thrombosis patients without a defined clotting defect to those of Factor V Leiden patients with a history of venous thrombosis and to those of healthy controls. 180 patients without a defined clotting abnormality and 73 patients with Factor V Leiden were prospectively followed after discontinuation of oral anticoagulants for venous thrombosis and F1+2 was measured at regular intervals. Recurrent venous thromboembolism occurred in 23 (9%) of the 253 patients. Before or at several time points after oral anticoagulants, no significant difference in F1+2 levels was found in patients with and without recurrent thrombosis. F1+2 levels at 3 weeks and prior to recurrence were not significantly different in both patient groups. Over a one-year observation period, F1+2 levels of both patients with and without Factor V Leiden were higher than those of the controls. No difference in F1+2 was seen between patients with and without Factor V Leiden. We conclude that monitoring of F1+2 is not suitable for identification of individuals at risk of recurrent venous thrombosis. Permanent hemostatic system activation is detectable both in patients with a defined abnormality of the clotting system and in patients in whom a particular defect has not (yet) been identified.

Adult↗

Newly diagnosed malignancy in patients with venous thromboembolism. Search or wait and see?

The incidence of newly diagnosed malignancy is increased in patients with unexplained venous thromboembolism during the first year after a thromboembolic event in comparison to controls (odds ratio, 3.9-36). Extensive screening with computed tomography, endoscopy and tumor markers can identify most of these undetected malignancies. However, approximately half of these can also be identified based on a simple clinical evaluation. Extensive screening has no demonstrated benefit and might actually cause harm. This consideration, combined with the economical and psychological costs of extensive screening leads to the decision not to use such screening procedures, unless indicated by clinical circumstances. Thus, it is appropriate to maintain a low threshold of suspicion for malignancy when treating patients with unexplained venous thromboembolism and to base the decision to perform additional diagnostic tests on the findings of an initial medical history, physical examination, routine laboratory tests and chest x-ray.

Clinical Trials as Topic↗

Incidence of thromboembolic complications after laparoscopic cholecystectomy: review of the literature.

The purpose of this study was to quantify the risk of thromboembolic complications after laparoscopic cholecystectomy by a survey of the literature. We reviewed 60 laparoscopic cholecystectomy series consisting of 153,832 patients. The average mortality was 0.08%. The average rate of fatal pulmonary embolism was 0.02% and total pulmonary embolism 0.06%. The average rate of reported deep vein thrombosis was 0.03%. We conclude that laparoscopic cholecystectomy is a safe procedure, and the rate of clinically evident postoperative thromboembolic complications is probably lower than after conventional cholecystectomy. A lingering bias due to the overrepresentation of young and healthy patients early in the era of laparoscopic cholecystectomy could, however, still affect these figures. An underreporting of the lesser complications is likely. The risk is not negligible, though, and some authors have recommended thromboembolism prophylaxis, although further studies are necessary to find the optimal prophylaxis strategy. The true incidence is possible to establish only by using objective diagnostic methods for surveillance.

Cholecystectomy, Laparoscopic↗

Low molecular weight heparin for the prevention and treatment of venous thromboembolism.

Low molecular weight heparin is effective for the prevention and treatment of venous thromboembolism. Low molecular weight heparin has the practical advantage that it does not require anticoagulant monitoring and dose adjustment. The simplified therapy provided by low molecular weight heparin will allow many patients with venous thromboembolism to be cared for in an outpatient setting, with a potential for major savings in health care costs. For preventing venous thromboembolism after hip or knee replacement, and after general abdominal surgery, further cost effectiveness studies are required to determine the ultimate clinical role of low molecular weight heparin.

Abdomen↗

[Study of the platelet aggregation inhibitor MICRISTIN as to its efficacy in the prevention of thromboembolism in the postoperative phase following surgical interventions].

Clinical test of the acetylsalicylic acid preparation micristin concerning effect and side-effect on the postoperative rate of thromboembolism in general surgery and traumatology. Prospective, randomized, checked double-blind study in 802 operated patients: 401 patients with micristin and 401 patients with placebo. Objectivization of findings in highly endangered patients by the radiofibrinogen test, ultrasonic doubler, venography of contrast medium, section. In total there were 149 thromboembolic complications = 18.6%. The placebo control group (401 patients) had 52 ensured deep venothrombosises and 8 fatal pulmonary embolisms. The group with micristin treatment (401 patients) had 23 ensured deep venothrombosises and 4 fatal pulmonary embolisms. Significant decrease of the thromboembolism rate by micristin (p = 0.001). Failures concerning the effect of micristin included fractures near the hip. Favourable effects concerned intra-abdominal surgery. Frequent side-effect: increased intra-operative and postoperative bleeding tendency.

Adolescent↗

Oral contraceptives and venous thromboembolism: an epidemiological review.

New epidemiological studies have demonstrated a higher risk of venous thromboembolism among users of oral contraceptives (OCs) with third-generation progestogens desogestrel or gestodene compared with users of OCs with second-generation progestogens levonorgestrel or norgestrel. As the absolute risk of venous thromboembolism among users of OCs in general is lower in the new studies than in previously published studies, and as several important potential confounders are not controlled for in the new studies, the real difference in risk of venous thromboembolism between users of third- compared with second-generation products may be smaller than indicated in these new studies. At the same time, the risk of myocardial infarction may be smaller among users of third- compared with users of second-generation products. Until further epidemiological data emerge, it is therefore difficult to make general recommendations other than to use OCs with a low estrogen dose, and to make individual recommendations based on age, individual wish, and individual risk factors.

Causality↗

[Plasma and urinary fibrin fibrinogen degradation products in a case of renal thromboembolism].

The authors examined the trend of plasma (FDPp) and urine (FDPu) fibrin-fibrinogen degradation products in a case of renal thromboembolism during atrial fibrillation. No alterations of FDP are reported in the literature for this renal pathology. This raises the question of whether this laboratory parameter is of diagnostic value during the course of renal embolism. The case concerned a patient who was admitted to the emergency ward with painful symptoms in his right flank. He was initially hospitalised with a diagnosis of right renal colic. A few days later multiple thromboembolism of the right kidney was diagnosed using CAT with i.v. infusion of contrast medium and renal scintigraphy with 99Tc DTPA. From day 6 to day 17 after the start of painful symptoms, a number of assays were made of FDPp and FDPu using the rapid latex test for FDP which uses specific anti-fragment D and E antiserum (Thrombo-Wellcotester). Alterations of plasma and urine FDP were found which also showed an opposite trend: an inversion of the changes was noted on day 8 with normalisation of FDPp and a persistent increase in FDPu by day 17. Earlier tests may confirm the trend of FDP and their value in diagnostic screening for cases of renal thromboembolism.

Adult↗

Venous thromboembolism in multiple trauma patients.

Thromboembolic complications are frequent in patients with multiple trauma. The efficacy of unfractionated heparin for venous thrombosis prophylaxis has not been established. Based on limited prospective data, low-molecular-weight heparin appears to be more effective than unfractionated heparin and at least as effective as compression devices for preventing thromboembolic complications in these patients. Vena cava filters should be considered in high-risk patients who cannot receive anticoagulant therapy, but long-term filter use without concomitant anticoagulant therapy is associated with a substantial risk of recurrent thromboembolism.

Bandages↗

[Prevention of venous thromboembolism. Survey of in-hospital medical practice].

OBJECTIVES: In an effort to improve the prevention of venous thromboembolism, the Nancy University Hospitals conducted a survey of medical practice concerning indications for preventive therapy and surveillance of platelet counts and anti Xa activity. METHODS: The survey involved 163 medical files. Questionnaires were filled out in 6 units (3 medical wards and 3 intensive care units). RESULTS: Indications for preventive therapy were found to be quite variable with the exception of very low risk of thromboembolism where the treat/do not treat ratio was 0.1/1, indicating a clear tendency for abstention. This ratio was 0.77/1 and 0.38/1 respectively for low and moderate risk and 2/1 for high risk. There was undoubtedly a ward effect. The attitudes in practice tended toward non-prevention in patients without limited mobility. For platelet counts, an initial count was performed in 95% of the cases and during treatment in 38% although the specific rates were not the same for different types of units. Anti-Xa activity, which according to prevention recommendations need not to be determined, was not monitored in 88% of the cases. In accordance with prevention recommendations, anti-Xa activity was not determined in 88% of the cases. CONCLUSION: Further progress is needed in the prevention of venous thromboembolism and should be based on wider use of existing methods.

France↗

The setting up and implementation of a venous thromboembolism prophylaxis policy in clinical hospital practice.

Clinical management policies are meant to lead to the delivery of better health care. However, as we demonstrate in this review, having an oral or written venous thromboembolism prophylaxis policy does not necessarily lead to the majority of general surgical inpatients receiving the appropriate prophylaxis. We discovered, through prospective clinical audit, that for a clinical policy to be effective in delivering the appropriate health care, it must be repeatedly scrutinized and implemented in the correct manner. Only after several rounds of the audit cycle were we able to achieve the deliverance of venous thromboembolism prophylaxis to the majority of general surgical patients on our unit. This has wider implications, not just for the implementation of a venous thromboembolism prophylaxis policy, but also for all clinical management policies, and illustrates the importance of clinical audit in clinical practice.

Guideline Adherence↗